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Development of a novel in vivo lung perfusion (IVLP) procedure permits localized delivery of 48 
high-dose doxorubicin (DOX) for targeting of residual micrometastatic disease in lungs. 49 
However, DOX delivery via IVLP requires careful monit ring of drug level to ensure tissue 50 
concentrations of this agent remain in the therapeutic window. A small dimension nitinol wire 51 
coated with a sorbent of biocompatible morphology (Bio-SPME) has been clinically evaluated for 52 
in vivo lung tissue extraction and determination of DOX and its key metabolites. The in vivo Bio-53 
SPME-IVLP experiments were performed on pig model over various (150 and 225 mg/m2) drug 54 
doses, and during human clinical trial. Two patients with metastatic osteosarcoma underwent 55 
bilateral pulmonary metastasectomy and were treated with a single 5 and 7 µg/mL (respectively) 56 
dose of DOX during a 3-h IVLP. In both pig and human cases, DOX tissue levels presented 57 
similar trends during IVLP. Human lung tissue concentrations of drug ranged between 15-293 58 
µg/g over the course of the IVLP procedure. In addition to DOX levels, Bio-SPME followed by 59 
liquid chromatography-mass spectrometry (LC-MS) analysis generated 64 features during 60 
endogenous metabolite screening, providing information about lung status during drug 61 
administration. Real-time monitoring of DOX levels in lung can be performed effectively 62 
throughout the IVLP procedure by in vivo Bio-SPME chemical biopsy approach. Bio-SPME also 63 
extracted various endogenous molecules providing a real-time snapshot of the physiology of the 64 
cells that might assist in the tailoring of personalized treatment strategy. 65 
 66 
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1. Introduction  71 
Pulmonary metastases are known to develop in approximately 30% of patients with 72 
malignant tumors, most frequently in patients suffering from sarcomas. Although surgical 73 
resection is a widely accepted treatment for pulmonary metastases, a 5-year survival rate of about 74 
20% after complete resection remains disappointing [1]. Unfortunately, most patients develop 75 
recurrent metastasis, probably as a result of microetastatic disease present at the time of the 76 
initial operation [2]. Most recurrences occur in the lungs themselves, suggesting that the lung is 77 
the major reservoir of occult metastatic burden (Fig. 1). Therefore, a treatment capable of 78 
specifically targeting the lung to eradicate micrometastatic disease would be highly beneficial for 79 
this patient population. By building upon our experience with ex vivo lung perfusion for repair of 80 
donor lungs for transplantation  [3,4], our group recently developed and described a technique for 81 
isolated in vivo lung perfusion (IVLP) to facilitate localized drug delivery to lungs during surgical 82 
resection [2,5]. Based on these pre-clinical studies, a phase I clinical trial (NCT02811523) using 83 
doxorubicin (DOX) during IVLP for treatment of lung sarcoma metastases is underway. 84 
Direct determination of DOX in different compartments of lung tissue is desired during 85 
IVLP as it would allow to monitor drug level and its biodistribution within particular lung lobes. 86 
Traditionally, accurate determination of DOX in lungs requires collection of tissue via biopsy, an 87 
invasive process that can only be performed from periph ral locations of the organ [6]. In 88 
addition, such method requires lengthy sample processing and analysis, thus preventing real-time 89 
determinations of concentration and distribution of DOX in lung tissue over the course of IVLP. 90 
The absence of such information during this procedur , in turn, introduces potential for 91 
administration of subtherapeutic or toxic tissue leve s of DOX. Therefore, a minimally invasive 92 
method capable of monitoring DOX levels in tissue in close to real-time conditions would allow 93 









implementation of such a monitoring tool during IVLP would be of critical therapeutic benefit, as 95 
such a measure would optimize treatment while preventing adverse effects associated with toxic 96 
levels of DOX in the target organ. Additionally, analysis of other molecular indicators such as 97 
metabolites could provide insight regarding individual patient’s response to drug toxicity or organ 98 
stress by providing insight into ongoing biochemical processes during IVLP [7]. Access to such 99 
information would be useful for effective tailoring of this treatment, as it would enable dose 100 
adjustments based on measurements of patient response rather than just DOX concentration 101 
levels. 102 
Herein, biocompatible solid phase microextraction (Bio-SPME) is proposed as a new 103 
analytical strategy to assist in real-time measurements of DOX in tissue and perfusate during 104 
IVLP. Bio-SPME has already been reported for analysis of tissues [8,9].  This chemical biopsy 105 
procedure involves the extraction of small molecules such as xenobiotics and endogenous 106 
molecules from a biological system by directly inserting sharpened microprobe the size of an 107 
acupuncture needle (ca. 0.3 mm diameter) into the tissue (Fig. 2) without removal of any tissue 108 
residue [10,11]. The probe consists of a nitinol (Ni/Ti) alloy wire coated with a matrix-compatible 109 
phase; in this case, a crosslinked slurry composed f micron-sized sorbent particles suspended in 110 
a biocompatible oligomer binder.  The crosslinked polyacrylonitrile oligomer forms a smooth 111 
surface characterized by small size pores, which exclusively permit the diffusion of small 112 
molecules from tissue to dispersed sorbent particles while preventing the adsorption of tissue 113 
components such as proteins, red blood cells, and other endogenous macromolecules onto the 114 
surface of the coating [11]. Recovery of these small compounds is obtained via their desorption 115 
from the coating into a small amount of organic solvent, which is then subjected to instrumental 116 
analysis. 117 
Quantitative analysis can be performed since Bio-SPME is conveniently amenable to a 118 









(HPLC) coupled to tandem mass spectrometry (MS/MS)  the standard method for bioanalytical 120 
determinations [12]. Qualitative analysis by way of untargeted metabolomics can also be 121 
performed via HPLC coupled to a high-resolution mass spectrometer (HRMS) [13]. SPME has 122 
shown great potential in the field of clinical metabolomics due to its extractive capabilities for a 123 
broad range of both polar and non-polar small molecules (100 – 1200 Da) [11,14]. The advantage 124 
of carrying out a chemical biopsy via solid phase microextraction (SPME) in comparison to 125 
several other approaches is that Bio-SPME could be used to perform in vivo metabolomics [14–126 
17]. Given its minimally invasive design, non-depletiv  extraction principle, and 127 
biocompatibility, information regarding the metabolites present within the system at a given time 128 
can thus be easily obtained without disrupting molecular binding or equilibrium within the 129 
system, nor damaging the microprobe itself [15]. In addition, Bio-SPME can be hyphenated to 130 
stand-alone mass spectrometer (MS) instruments, resulting in shorter analysis times and closer to 131 
real-time in vivo monitoring of DOX levels [15]. The herein proposed approach certainly fits 132 
within the growing trend of incorporating intraoperative real-time analysis of small molecules in 133 
animal and human studies via automated MS-based diagnostic protocols. Devices such as 134 
intelligent Knife (iKnife), MasSpec Pen, and SpiderMass are among modern biocompatible tools 135 
that enable easy and fast introduction of extracted analytes to MS instrumentation, thus providing 136 
access to relevant information regarding the status of tissue during surgery [18–20]. In line with 137 
these trends, the development of sampling/sample preparation techniques based on microdialysis 138 
(MD) and SPME for such applications has observed increased demand in recent years, as such 139 
techniques facilitate reliable in vivo measurements of drug concentration and biodistribution 140 
within selected organs [10,11,21]. 141 
Here, Bio-SPME is used to monitor DOX and its metabolites, as well as small endogenous 142 
molecules, present within the system over the course of IVLP. The current work presents the 143 









various drug doses as a proof-of-concept and (ii) in vivo IVLP human clinical trials. The work 145 
also demonstrates that the SPME chemical biopsy captures other low molecular weight 146 
compounds, such as potential markers of drug toxicity or organ stress over the course of IVLP. 147 
 148 
2. Materials and Methods 149 
2.1. Experimental procedures 150 
The experiments were performed on (1) in vivo pig model over various (150 and 225 151 
mg/m2) drug doses and (2) during in vivo IVLP human clini al trial. Two patients with metastatic 152 
osteosarcoma (first patients underwent bilateral pulmonary metastasectomy) were treated with 5 153 
and 7 µg/mL (respectively) dose of DOX during a 3-hIVLP. Concomitantly, perfusate samples 154 
were collected at the same time points as in vivo SPME sampling time points in order to analyze 155 
the level of DOX during IVLP. The assessment of DOX concentration was performed with the 156 
use of previously optimized method [22]. In addition, we investigated in vivo profile of small 157 
endogenous molecules in human lung tissue over the course of IVLP-DOX administration. For 158 
metabolomics data analysis, LASSO (Least Absolute Shrinkage and Selection Operator) was 159 
applied for selection of variables prior to chemometric analysis. IVLP procedure and Bio-SPME 160 
lung sampling were conducted at Toronto General Hospital. Bio-SPME extraction of perfusate 161 
samples was performed on-site at Toronto General Hospital and in the analytical laboratory at 162 
University of Waterloo. HPLC-MS/MS and HPLC-HRMS analyses were performed in the 163 
analytical laboratory at University of Waterloo. For the studies the prototype SPME-164 
biocompatible mixed-mode (MM) fibers with C8+benzenesulfonic acid particles were used as in-165 
kind contribution of Supelco (Bellefonte, PA, USA). 166 









Two Yorkshire pigs weighing approximately 35 kg were used. A porcine left lung IVLP 168 
model was used to model delivery of high doses of DOX during IVLP. The IVLP model 169 
procedure has been described elsewhere [2,5]. The doses of DOX administered were 150 and 225 170 
mg/m2. SPME sampling was performed from the lower lobe of the left lung before perfusion (t0) 171 
and 30, 90, 150, and 210 min after the start of the IVLP procedure, using the protocol described 172 
below. The study was approved by the Animal Care Research Committee at Toronto General 173 
Research Institute. 174 
2.3. In vivo human study 175 
The clinical trial was registered www.clinicaltrials.govin the clinical trial registry, and 176 
institutional research ethics board approval was obtained. Two individuals were enrolled in the 177 
clinical study: 22-year old and 66-year-old males with bilateral recurrent pulmonary metastases 178 
secondary to osteogenic sarcoma (Fig. 1). All lung lesions treated with DOX using the IVLP 179 
platform were resectable with wedge or segmental resections. First patient had previous systemic 180 
exposure to DOX (<450 mg) and had previously received a bilateral metastatectomy. The 181 
technical details of the procedure have been described elsewhere [5]. Briefly, a clam-shell 182 
thoracotomy was performed and the left pulmonary hilum was dissected. The pulmonary artery 183 
and upper and lower pulmonary veins were dissected and subsequently cannulated and attached to 184 
the IVLP perfusion system. Lung isolation was performed using vascular clamps, and IVLP was 185 
initiated and run for 3h. Doxorubicin was added to the IVLP perfusion solution at a concentration 186 
of 5 and 7μg/mL for the first and second patient, respectively. 187 
For Bio-SPME sampling of lung, three fibers (Fig. 2) were placed in different areas of the 188 
lung (upper, middle, and lower sections) at predetermined time points over the course of the 189 
surgery. The lung was sampled prior to drug administration, hourly during IVLP, and once after 190 
reperfusion. Extractions were carried out for 20 min under static conditions. For Bio-SPME 191 









20-min static extraction was performed on these samples as well. For both Bio-SPME sampling 193 
cases, the fibers were subsequently rinsed manually in water for 5 s, wiped with a Kimwipe, and 194 
immediately snap frozen in dry ice. Additional perfusate samples were also collected and snap 195 
frozen in dry ice until further analysis in the laboratory. Doxorubicin concentrations in lung and 196 
in perfusate were determined in accordance with the rec ntly published and validated SPME-197 
HPLC-MS/MS protocol with some minor modifications. Detailed information regarding the type 198 
of fibers employed and instrumentation for analysis can also be found elsewhere [22]. In addition, 199 
the analytical method to identify and quantify DOX key metabolites (doxorubicinol (DOX-ol), 200 
doxorubicinone (DOX-one), and doxorubicinolone (DOX-olone)) has been developed. A brief 201 
description of analytical conditions employed (during the drug and its metabolites’ determination) 202 
together with materials used has been included in the Supplementary Material. 203 
2.4. Statistical analysis 204 
The metabolomics experiments were performed separately for both cases because of the 205 
long-time interval between the recruitment of the patients. First dataset was used for selection of 206 
important endogenous features, while the second dataset was used for confirmation of the initial 207 
findings. In metabolomics experiments, the number of features detected is typically much larger 208 
than the number of samples studied. In our study, the first dataset consisted of n = 12 samples and 209 
p =138 variables. Selection of variables prior to chemometric analysis was carried out using the 210 
LASSO method. LASSO (Least Absolute Shrinkage and Selection Operator) applies a 211 
regularization process where it penalizes the coeffici nts of regression variables, forcing certain 212 
coefficients to be set to zero. Thus, LASSO removes variables that are redundant by effectively 213 
providing a simpler model that does not contain those coefficients. The number of variables 214 
selected using the LASSO method has to be smaller or qual to the number of samples. Moreover, 215 
LASSO will often select only a single feature from a set of highly correlated variables [23]. 216 









Variance scaling). Principal component analysis employed internal cross-validation using the 218 
Leave-one-out (LOO) method.  The validation metrics root mean squares errors of calibration 219 
(RMSEC) and cross-validation (RMSECV) were calculated. 220 
 221 
3. Results and Discussion  222 
3.1. Determination and quantification of DOX during IVLP 223 
As a proof-of-concept for the sampling method, initial experiments were carried out using 224 
pigs as the experimental model. No bleeding or adverse ffects were observed in any of the 225 
sampled areas of the lung (Fig. 3). Stability and biocompatibility of the probes was proven 226 
previously on several in vivo animal models like fish, mice, rats, pigs, monkeys [15]. The organ 227 
samplings included liver, lung, kidney, brain and muscle, i.e. tissues of different texture, density, 228 
resistance and other properties. As mentioned before, the core of the probe is made from nickel-229 
titanium alloy, which gives them a shape-memory and prevents breakage during tissue 230 
penetration, while the extractive phase particles are effectively immobilized on the mentioned 231 
metal support by polyacrylonitrile. The only modification which was made in the present 232 
samplings is the angle of cutting the tip of the fiber. The blunt end can easily penetrate soft tissues 233 
like liver or brain, but in case of more resistant tissues like muscle or lung (presence of pleura) 234 
pre-piercing with needle or use of pointed tip or guide cannula is needed. Single Bio-SPME probe 235 
from each time point was used to assess lung tissue concentration of DOX. Lung tissue 236 
concentrations of DOX were successfully measured during two separate IVLP procedures, where 237 
DOX doses of either 150 mg/m2 or 225 mg/m2 were administered (Fig. 4). As expected, sampling 238 
before DOX administration (time zero, pre-IVLP) did not show the presence of the 239 
chemotherapeutic agent in lung tissue. Subsequent samplings exhibited a trend of a quick peak of 240 
drug followed by steady decline. For the lung perfused with a drug dose of 150 mg/m2, a 241 








was initiated. For the lung perfused with a dose of 225 mg/m2 DOX, a maximum measured 243 
concentration of 3521 µg/g was reached after 90 min of IVLP. In the case of the high dose (225 244 
mg/m2 DOX), the whole procedure ceased at 150 min, as the animal did not tolerate the injury 245 
caused by the high dose being administered. 246 
In the human study, two patients, one aged 22 and the other aged 66, underwent the IVLP 247 
procedure. There were no intra-operative complications and use of Bio-SPME probes did not 248 
cause lung injury. For the first patient (22-year-old), wedge resection was performed for 6 lesions 249 
on the right lung and 4 lesions on the left lung. Total operative time was 7 h 19 min in the case of 250 
22-year-old patient and 6 h and 47 min in the case of 66-year-old patient. Both patients tolerated 251 
the procedure well and did not require Intensive Care Unit (ICU) admission. Each patient was 252 
discharged home on postoperative day 7 (POD7). They had an uneventful post-operative period 253 
and returned to regular activity after 1 month. At 6 months, the first patient’s forced expiratory 254 
volume in one second (FEV1) decreased from 4.7L (82% predicted) to 2.9L (50% predicted) and 255 
his forced vital capacity (FVC) decreased from 5.6L (80% predicted) to 3.4L (48% predicted). 256 
The patient developed bilateral lung recurrences after 6 months of follow-up, which have 257 
progressed despite further treatment. He remained alive until 1 year of follow-up. The second 258 
patient remained in overall good health at 6-months of follow-up. 259 
For the 22-year old patient, concentrations of DOX in the upper, middle, and lower 260 
regions of the perfused lung showed similar trends during IVLP (Fig. 5A). Expectedly, before 261 
perfusion started (pre-IVLP), lung tissue was free of DOX. Maximum lung tissue concentrations 262 
of drug measured by Bio-SPME-LC-MS/MS method were rached at the first hour of IVLP, and 263 
were 200 µg/g, 36 µg/g, and 166 µg/g, for the upper, middle, and lower sections of the lung, 264 
respectively. Lung tissue concentration dropped steadily over the course of IVLP and reached a 265 
minimum of 14 µg/g, 8 µg/g, and 9 µg/g for the upper, middle, and lower areas of the lung, 266 









(current gold standard technique done in tissue biopsies to measure DOX), which consisted of 268 
protein precipitation (PPT) followed by HPLC with fluorescence detection (HPLC-FLD), showed 269 
a DOX concentration of 7.0 µg/g in the biopsy tissue 30 min post-reperfusion. Further details on 270 
the hospital assay employed have been published elswhere [6]. For the 66-year old patient, the 271 
highest tissue concentrations of DOX estimated with B o-SPME probes were also noticed in the 272 
first hour of lung perfusion, and were 179 µg/g, 69 µg/g, and 293 µg/g, for the upper, middle, and 273 
lower sections of the lung, respectively (Fig. 5C). Similarly, to the first human case, lung tissue 274 
concentrations of DOX exhibited a decreasing trend throughout the procedure reaching the levels 275 
of 30, 18 and 28 µg/g for the upper, middle, and lower areas of the lung, respectively 30 min post 276 
blood reperfusion. The hospital assay utilizing collected biopsy samples predictably revealed no 277 
drug at the stage of pre-perfusion and its very lowcontent during pulmonary reperfusion (Fig. 278 
5C). 279 
In addition to in vivo tissue measurements of DOX and its metabolites, the drug was also 280 
extracted by SPME probes on-site as well as in the analytical laboratory from perfusate samples 281 
collected at the same time points used for the in vivo lung sampling. For the 22-year old patient, 282 
the total drug dose given to the perfusion circuit was 5.0 µg/mL. Concentration of DOX in the 283 
perfusate decreased steadily from the beginning of the IVLP procedure (Fig. 5B). SPME-HPLC-284 
MS/MS analysis revealed that after 30 min, the DOX concentration in the perfusate was 2.4 285 
µg/mL and that over the course of the procedure this value decreased to a minimum of 0.3 µg/mL 286 
by the end of the perfusion. PPT-HPLC-FLD analysis of perfusate samples performed by the 287 
clinical laboratory showed a concentration of 7.2 µg/mL after 30 min, and a nadir of 1.0 µg/mL 288 
by the end of the perfusion. DOX concentration measurements of frozen perfusate samples 289 
analyzed by SPME-HPLC-MS/MS after transport to an off-site location showed no statistically 290 
significant differences from perfusate samples analyzed by SPME in the operating room (p = 291 









circuit was 7 µg/mL and detected concentration of DOX in the perfusate samples in the first hour 293 
of the procedure was 2.66 µg/mL. In next hours of IVLP, DOX level decreased to 1.16 µg/mL at 294 
the 3rd h of perfusion (Fig. 5D). For the 66-year old patient, a similar decreasing trend in the 295 
terms of the drug level in perfusate samples over th  course of IVLP was also observed with the 296 
standard approach employing PPT as a streamlined sample preparation method (Fig. 5D), 297 
however using the same instrumental method and analytical conditions the results received with 298 
two different strategies were even more comparable. Figures 5B and 5D present a direct 299 
comparison of SPME results with standard assays showing relatively good match between the 300 
data.  In case of Fig. 5B the PPT-HPLC-FLD assay was performed by external clinical lab for 301 
single samples at each time point, while in Fig. 5D the PPT-LC-MS assay was performed on 302 
triplicate samples, similar as SPME extraction. It should be noted that the estimated precision 303 
obtained for SPME (RSD below 5%) was much better compared to PPT-LC-MS (RSD below 304 
15%). 305 
Furthermore, the identification and quantification f key metabolites of DOX, namely 306 
doxorubicinol (DOX-ol), doxorubicinone (DOX-one), and doxorubicinolone (DOX-olone) was 307 
performed for both clinical cases. However, the results showed that DOX metabolites were 308 
present at trace levels in the tested matrices (Fig. 6). Only DOX-ol formed in the major metabolic 309 
route of DOX metabolism was detectable at visible leve , but its content in lung tissue did not 310 
exceed 5% of the intact drug, and therefore was conidered as insignificant. 311 
The current study demonstrates that the developed mthod based on SPME enables 312 
quantitative monitoring of DOX from lung tissue in a safe and minimally invasive manner. 313 
Multiple insertions of Bio-SPME chemical biopsy probes did not cause tissue injury during in 314 
vivo administration in either pig or human lungs. Each patient recovered uneventfully and had no 315 
complications from the SPME fiber insertion or the IVLP-DOX administration. Bio-SPME 316 









processing were done in the analytical lab. No difference was observed among perfusate results 318 
for analyses carried out on-site or in-lab; however, the availability of MS instruments within or 319 
near the operating room would offer the possibility of more rapid target drug concentration 320 
determinations. A fully on-site setup is feasible since Bio-SPME probes can be directly coupled to 321 
a mass spectrometer (SPME-MS), thereby providing results within seconds [15,24,25]. More 322 
recently we have also developed portable fluorometer coupled to laptop designed to be deployed 323 
in a surgery room for fast and direct quantification f DOX in the tissue via detection of this 324 
compound in the SPME coating [26]. Fluorescence readout, however, can only provide the 325 
information about DOX concentration, but not about its metabolites or endogenous compounds, 326 
hence the information about organ condition in respect to biochemical alterations still requires the 327 
application of MS analysis. 328 
In both pig and human cases, DOX tissue levels present d similar trends during IVLP, 329 
wherein drug concentrations peaked between sixty to ninety minutes after the start of IVLP and 330 
subsequently dropped. This is more evident in the clinical trial since all sampled areas of the lung 331 
– upper, middle, and lower – exhibited the same pattern. As there were no measured leaks in the 332 
IVLP circuit, two potential reasons may explain this observed pattern: a) biotransformation of 333 
DOX into metabolites, leading to less intact drug available for extraction (that was rather not 334 
supported by our results indicating the formation of negligible amount of metabolites) or b) 335 
diffusion of DOX into cells. Bio-SPME probe extracts only free concentration of compounds, and 336 
therefore will not remove DOX bound to the intracellular components [17]. The binding or 337 
partitioning of DOX into cells, therefore, decreases its free concentration in the extracellular 338 
environment of the lung where the microprobe performs sampling, which is reflected in the trend 339 
of decreasing DOX concentration. The results of DOX level obtained by Bio-SPME-HPLC-340 
MS/MS for the lower lobe of the lung after drug washout (9 µg/g for first human case and 28 µg/g 341 









standard assay further confirming the reliability of the approach proposed. Furthermore, the 343 
results from this study indicate that perfusion of the lung does not necessarily provide 344 
homogenous drug distribution, which may also account for the slight difference between the 345 
results provided by each assay, as the samples, although derived from the same lobes, were not 346 
obtained from the exact same location. It is important to emphasize that the differences in sample 347 
preparation fundamentals between SPME and PPT as well as much broader calibration range used 348 
in detection method by the clinical lab contributed o some differences in the results gathered for 349 
perfusate samples employing these two methods. Furthermore, Bio-SPME has the added 350 
advantage of providing information about the total as well as free drug concentrations; the latter 351 
offering the drug fraction immediately available for tissue binding [15,17]. Despite some 352 
differences in absolute measured DOX concentrations between the SPME-HPLC-MS/MS and 353 
standard assays, more evident with PPT-HPLC-FLD method and less pronounced with PPT-LC-354 
MS method (and comparable calibration curve range), as seen on Fig. 5B-D, there was  a coherent 355 
decreasing trend observed by both techniques, showing reliability and relative agreement of the 356 
methods. In addition, although the developed Bio-SPME-LC/MS method also offers a possibility 357 
to monitor DOX key metabolites (DOX-ol, DOX-one and DOX-olone), none of them were found 358 
at significant level in the lung tissue during DOX administration via IVLP. This finding is in line 359 
with generally accepted assumption that intact drug rather than its metabolites is responsible for 360 
pharmacological activity and anticancer effects [27,28]. 361 
 362 
3.2. Screening of small molecules in lung tissue during IVLP-DOX administration 363 
As demonstrated in previous studies, SPME is suitable for extraction and monitoring of a 364 
broad range of metabolites (from highly hydrophilic to hydrophobic ones) in different biomatrices 365 
[29], including unstable compounds, like oxylipins, which was recently reported in brain studies 366 









DOX via HPLC-MS/MS analysis were also used for screening of other low molecular weight 368 
compounds via HPLC-HRMS. Figure 7 shows the principal component analysis (PCA) conducted 369 
on samples obtained for the 1st clinical case at different time points for the duration of IVLP. It is 370 
evident that samples collected from each time point group relatively well together, with 371 
separation seen as a transitionary pattern from the left to the right part of the plot. It was even 372 
more pronounced for 2nd clinical case pointing at a clear discrimination among metabolomic 373 
patterns for samples collected before commencing perfusion, during IVLP, and reperfusion (Fig. 374 
S1).  375 
Introduction of LASSO analysis enabled selection of the features (compounds) of the 376 
highest importance in the separation between subseqent time points of the experiments: T0, T1, 377 
T2, and T3, or between T0 and T3 only (before IVLP and after reperfusion). It should be 378 
emphasized that after the IVLP procedure, lungs were flushed with perfusate not containing DOX 379 
(reperfusion) in order to remove any remaining drug from the isolated organ, thereby avoiding 380 
systemic side effects. As expected, among the featur s differentiating all four time points were 381 
doxorubicin and several other molecules of possible endogenous or exogenous origin. The biplot 382 
in Figure 7 represents the relationship between the data collected at given time points during 383 
IVLP for all three lobes of the lung, and masses of importance selected by LASSO. Penalized 384 
regression methods such as the LASSO have proved useful for variable selection in many fields 385 
especially for situations with high-dimensional data where the numbers of variables far exceed the 386 
number of samples. LASSO identify a set of metabolites that are relatively important in relation 387 
to a given outcome. Indeed, there are some drawbacks of LASSO, e.g. it may not recover the full 388 
sparsity pattern when p ≫ n and is sensitive for the highly correlated variables. Despite the 389 
presence of collinearity, LASSO can still distinguish between important variables. The size of the 390 









the cluster of correlated predictors. Moreover, in many high-dimensional metabolomic datasets it 392 
is reasonable to assume that a small number of compounds are relevant for the outcome [31, 32].  393 
Additionally, correlation analysis performed between all detected features and DOX lung 394 
concentration and distribution resulted in a number of metabolites exhibiting statistical 395 
significance. Cases where the statistical significance was observed in at least two lobes were 396 
subjected to further identification and biological interpretation. The list of selected masses and the 397 
biplot plotted for the aforementioned metabolites can be found in Supplementary Information 398 
(Table S2 and Fig. S2, respectively). Putative identification of the presented features enabled 399 
selection of those of important biological significance, namely compounds related to lung toxicity 400 
or injury. One of the identified endogenous compounds was 5'-methylthioadenosine (MTA), 401 
which showed a negative correlation with DOX (Fig. S2) over the course of IVLP. 5'-402 
methylthioadenosine levels were found to increase throughout IVLP and after reperfusion. 403 
Another interesting feature identified in SPME extrac s from different sampling time points 404 
during IVLP was creatine riboside (CR) (Fig. 8E and 8F). Similar to MTA, CR also shows a 405 
negative correlation with DOX level. In addition, the Bio-SPME approach was capable of 406 
detecting alterations in several lipid classes. Among them, cardiolipins correlated negatively with 407 
the level of DOX at different time points of the IVLP. 408 
Changes in the profiles of endogenous compounds corresponding to the administration of 409 
DOX during IVLP were monitored to verify if the analytical strategy proposed for drug 410 
monitoring could also be adopted for screening of known markers of drug activity. As a proof of 411 
concept, compounds that showed correlation with DOX activity including MTA, and cardiolipins 412 
(CLs), as well as the biomarker of lung cancer, CR,were putatively identified in sample extracts. 413 
Presence of the metabolites was reported in the first case and further confirmed in the second one. 414 
It has been previously reported that MTA exhibits proapoptotic effects on different cancer cells 415 









proposed to provide mechanisms to evade drug-induced apoptosis in tumor cells [35]. It has been 417 
suggested that MTA may have a dual role in the regulation of cellular homeostasis; therefore, 418 
further investigation of the relationship between MTA-DOX during IVLP should be performed on 419 
a larger cohort of patients/cases. DOX has also been pr viously shown to exhibit a strong 420 
correlation with lipid metabolism. In a rodent model, DOX led to elevated serum triglyceride and 421 
blood glucose levels through the down-regulation of peroxisome proliferator-activated receptor γ 422 
(PPARγ) [36]. An in vitro study with parental (MCF-7/S) and DOX-resistant (MCF-7/Dox) 423 
human breast cancer cells demonstrated that lipid profile changes can mediate the modulation of 424 
membrane fluidity in drug resistant cells [37]. The authors observed an increase in the levels of 425 
several lipids, including cardiolipins, in resistant cells. Interestingly, DOX was already described 426 
as a specific probe for transversal distribution of cardiolipin [38,39]. As it can be seen in Fig. 8 427 
MTA and cardiolipin (68:4) levels were elevated during the IVLP, while creatine riboside was 428 
found in the extract obtained at all time points, i.e. t was independent on DOX administration 429 
(Fig. 8). CR is considered a product of high creatine levels and high phosphate flux due to the 430 
higher energy demands of rapidly dividing tumor cells [40]. The level of this compound has been 431 
found to be significantly higher in the urine of patients with non-small cell lung cancer (NSCLC) 432 
compared to healthy individuals [41,42]. Moreover, it has been previously reported that increased 433 
levels of CR are associated with increased tumor size and poor prognosis. Therefore, it has been 434 
speculated that this compound may not only be useful as a marker of early detection of lung 435 
cancer, but also aid in the provision of more accurate prognoses [41]. Based on our finding it can 436 
be postulated that MTA, cardiolipins and CR may be promising targets for further study in 437 
SPME-based DOX activity evaluation during IVLP. More ver, as the first attempt at real-time 438 
profiling of metabolites in human lung tissue exposed to chemotherapy, this case study provides 439 









However, the results of metabolite screening, althoug  promising, contain limited data to 441 
draw any concluding remarks as the analyses in this case study were carried out in extracts 442 
specifically obtained for DOX analysis, and most of the small molecules described in this paper 443 
had low sensitivity. Therefore, as a next step, an optimum sample preparation protocol should be 444 
implemented to improve recovery of compounds of interest other than DOX. This will facilitate 445 
more in-depth study of organ-specific mechanisms as well as the adverse effects of DOX action, 446 
as such analyses are usually conducted on a large number of samples to account for biological 447 
variability and improve reliability of significant findings.  448 
 449 
4. Conclusions 450 
This work presents the first successful clinical use of the in vivo Bio-SPME chemical 451 
biopsy approach. The sampling/enrichment tool was used to reliably measure drug concentrations 452 
in lung tissue during a clinical case of localized DOX delivery. At the same time, a wide range of 453 
other molecules were extracted for metabolomic analysis, demonstrating the potential of the 454 
technique for real-time monitoring and early indication of lung toxicity and injury during the 455 
procedure. Based on these results, Bio-SPME can be used as a tool to assist in the safe and 456 
efficacious implementation of IVLP treatment for local chemotherapy by offering temporal and 457 
spatial monitoring of the drug concentration in indivi ual patients. The Bio-SPME chemical 458 
biopsy tool provides significant advantages as a novel approach for tissue sampling since it 459 
imparts real-time information about both the levels of the administered chemotherapy, as well as 460 
its effect and toxicity, as represented by the changing metabolomic landscape in the organ. Bio-461 
SPME also shows potential as a complementary technique to aid in the elucidation of pathways 462 
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Fig. 1. Pre-operative lung computed tomography (CT) scan for 1st patient subjected to IVLP 639 
showing numerous bilateral pulmonary sarcoma metastase  as denoted by arrows. 640 
 641 
 642 
Fig. 2. Biocompatible solid phase microextraction (Bio-SPME) microprobe. 643 
 644 
 645 
Fig.3. In vivo sampling of pig lungs during IVLP. A: tripl cate of Bio-SPME probes during 646 












Fig. 4. Concentration profile of DOX in lower lobe of the lung during IVLP (sampling points 30, 651 
90, 150, and 210 min). Red circles and blue squares – l vels of DOX after administration with 652 
150 and 225 mg/m2, respectively. 653 
 
Tissue Doxorubicin Levels during 1st Clinical IVLP
















































Tissue Doxorubicin Levels during 2nd Clinical IVLP






















































Fig. 5. Concentration of doxorubicin measured by Bio-SPME-HPLC-MS/MS in lung tissue 656 
during first (A) and second (C) clinical IVLP. Time points include 1h pre-IVLP, 1, 2, 3h during 657 
IVLP, and 30 min post-IVLP during lung reperfusion. Green, blue, and red dots represent the 658 
three locations of the fiber in the lung during sampling. The green triangle designates the upper 659 
section of the lung, the blue square designates a section between the upper and lower lobes 660 
(middle) of the lung, and the red circle designates th  lower section of the lung. Black diamonds 661 
show when hospital biopsies were taken. (B, D) Concentration of doxorubicin in perfusate as 662 
measured by Bio-SPME-HPLC-MS/MS and the standard approach (hospital assay - PPT-HPLC-663 
FLD or PPT-LC-MS) during human IVLP, represented bythe blue and red diamonds, 664 
respectively. Results are presented as mean ± SD. Statistical significance was determined by a 665 
two-tailed t-test; ns, *, ** , and *** indicate not significant, P < 0.05, P < 0.01, P < 0.001, 666 
respectively. 667 
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Fig. 6. Floating bars presenting levels of doxorubicin and its key metabolites (doxorubicinol and 671 
doxorubicin aglycone) over the course of IVLP procedur . The detection range together with 672 
median values for each compound analyzed in relevant m trixes (lung tissue (A, B) or perfusate 673 
samples (C-E), respectively) have been denoted. As indicated above, the intact drug was a 674 
predominant one detected in investigated systems with some amounts of metabolites resulting 675 













Fig. 7 Principal component analysis showing separation of the data obtained at subsequent time 681 
points for different sections of the lung; red circles denote baseline sampling, before IVLP; green, 682 
blue, and turquoise circles denote 1 h and 2 h after the start of IVLP and 30 min after the start of 683 
blood reperfusion (RMSEC = 0.462, RMSECV = 0.838), respectively. The biplot reflects the 684 
distribution of molecular features (compounds), denot d as grey points, selected with LASSO 685 
with respect to subsequent data points. 686 
   1st Clinical IVLP     2nd Clinical IVLP 687 
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Fig. 8. Scatter plots showing relative intensities of selected features/metabolites primarily 691 
dysregulated upon one-time chemotherapy treatment for an individual patient. Each dot in the 692 
scatter plots represents an individual metabolite in ach sample. 1st Clinical IVLP refers to 22-693 






















































































































































 Temporal and spatial monitoring of DOX concentration in individual patients with the 
use of Bio-SPME provides real-time information about the level of chemotherapeutic 
drug administered to the lungs 
 Bio-SPME probes enable quantitative analysis of DOX from lung of the living 
organism in a safe and minimally invasive manner as the microprobes do not cause 
tissue injury 
 In addition to drugs, in vivo Bio-SPME captures other low molecular weight 
compounds, such as potential markers of drug toxicity or organ stress during IVLP 
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